{"name":"Synthon BV","slug":"synthon-bv","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Glatiramer Acetate (GTR)","genericName":"Glatiramer Acetate (GTR)","slug":"glatiramer-acetate-gtr","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"}]}],"pipeline":[{"name":"Glatiramer Acetate (GTR)","genericName":"Glatiramer Acetate (GTR)","slug":"glatiramer-acetate-gtr","phase":"phase_3","mechanism":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses, reducing autoimmune attack on myelin.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Clinically isolated syndrome (CIS) with high risk of MS"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-09-05","type":"pipeline","source":"ET Pharma","summary":"Zydus ties up with Synthon BV for multiple sclerosis drug launch in US - ET Pharma","headline":"Zydus ties up with Synthon BV for multiple sclerosis drug launch in US","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-05","type":"regulatory","source":"BusinessLine","summary":"Zydus ties up with Synthon for US generic drug; Jagsonpal names new CEO; Biocon gets USFDA observations - BusinessLine","headline":"Zydus ties up with Synthon for US generic drug; Jagsonpal names new CEO; Biocon gets USFDA observations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNSnpXM2V5NW9ISkF3SlRxX0Nac05PMlVqRFB3VUo3dmRIUTZNTl90Q1h4OUpOLTN6U1VodTJnSlVieHNSSDBoUlpnM3VlaDlxNS1Jd1ZYZFJGclN3NzVDdTBGaGZpa0NPblBVbTZ2MDdBMVJxMmtuYUVrelZRdERYcW82bF9LSUE4eXFJSzg1ME1xR2dOU0pv?oc=5","date":"2025-09-05","type":"pipeline","source":"Equitypandit","summary":"Zydus Life Shares Gain 2% as Arm inks Agreement With Synthon BV - Equitypandit","headline":"Zydus Life Shares Gain 2% as Arm inks Agreement With Synthon BV","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-05","type":"deal","source":"The Economic Times","summary":"Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market - The Economic Times","headline":"Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRm9NdG5VSFl4RUpORE1zZWdJNGpaX3NFdHdBSWRHY2JPa1Q5aFdjVVBGa2QwLTZXT0ZvVGNYQ2xoRkFmMzM2WjNRZXB0S3NLeDFhbzNla2g1RGlQdlJXUEJPemhDUDJUNkhDLUE3ZmVLV2ZwRUhPLU1MQURKQmhxekRyOUVyQ09nbGY1Ym01d3BPdk1heXQ4aG15R1J0WGNMNEhCeVZiUHJtTkZfWlN3cnp3X0xvbWpKenB3TktDNks?oc=5","date":"2025-09-04","type":"pipeline","source":"Contract Pharma","summary":"Zydus, Synthon Enter Exclusive Licensing and Supply Pact for Ozanimod Capsules - Contract Pharma","headline":"Zydus, Synthon Enter Exclusive Licensing and Supply Pact for Ozanimod Capsules","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOcHJ3UWQ1M29oSkJiUXY3TWw4bGdIZEZPek9NQWkwTThiU0tBRVlsTkdFajZDb2dDR0drdUhsbzhmalZuRUVHZkFSNkFnVjlMY2RMelo4VG5WekpsMi1VSk9sTU94aGVRdE9PTDhJRDJHQ1AzQzJVZ0pCTVNQWU9hUGhXRjFQd2Z1anVuUEkyaGhUaTZXWVFlRXBwOHhERFZacENXYi0wdlUwS3NUcURqakRLOWw0ZkVzZFZqSktjako0bVY2dlpEY1F5VmVMV2hYTkhuQjlaajl6UF9zaEVncEgyZFg3czJJUENTSnp5d1dPQmxmeU9MUjRtX3hydjduN1RsWUY1M1U4UWwySFhMYUt5ZHNsSE9xemo5TnVRVQ?oc=5","date":"2025-09-04","type":"patent","source":"Newswire Canada","summary":"Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market - Newswire Canada","headline":"Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSI","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-02-13","type":"pipeline","source":"Medical Dialogues","summary":"Zydus Lifesciences, Synthon ink pact for new oncology product - Medical Dialogues","headline":"Zydus Lifesciences, Synthon ink pact for new oncology product","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOX0lMODdzZ2FCeFlQNndiVlR4UkszMzBFUmV5LVJseGs2eEM4SFE3czN5aXR4X2Q4UVRmaG5SWktMZWMxLW10NjlvcVNhWHR0WGtqR1E3N1ZURmRhcTRHdjd0V3RfOW1ObXdOWmFrSlFZQUxMalRPUUtkSXk0eS1EQnVCb0hDYlA5dThMMVZxcnZJX3BOUDNXb1NTTGNkSU1kV3YzYnpRSDRaVEHSAbABQVVfeXFMTmtZSVd2TC1lQTRRR2pVS3VwZGM2UWNTdGUyRThBWWVSSF9hOEEzSWNud3BIOVJjM2lRajBVTE5iYTNRLS1RblYyc2NDTGtrcHBWaDZ5WFBBTHFMSVBRVGV2eUc5S19OYy1MdkNfNFFqY0JqUUFNTTBhTzdLcndXbkg3Ml9mSTJSMExvQW8yVVNmOGdET0RJVTNWbWJKZnFFNjBJVkg2UWM3eTdYWU0yMHo?oc=5","date":"2025-02-12","type":"pipeline","source":"Express Pharma","summary":"Zydus Lifesciences signs agreement with Synthon BV for 505(B)(2) oncology product - Express Pharma","headline":"Zydus Lifesciences signs agreement with Synthon BV for 505(B)(2) oncology product","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQUXk4X0dZZWlQd2FWb1pleV85cEU2bDJDSzVHWER2M0FESDIwcUVWY0xfU2J5SVlWWHJqVlQ0TUtBb1pnZXd4emc2NDRjOGFMaHpaUUIxUXlfZzdPc1k0cnFxdXBaNUM2TWlJNldtVHRhZWhYLTJTYVNFQWlzaDlaNkJ6aUJYRzYxWGxheHN3aW1Yc3BUV3VRRXRuRmRHcWNVZ1E5T3YxbXFjSlk3TTRVQU5Eemd1VDVlMmt6Zkh4VjJic0hxTVE?oc=5","date":"2025-02-12","type":"pipeline","source":"BioSpectrum Asia","summary":"Zydus and Synthon to commercialise novel 505(B)(2) oncology product in US market - BioSpectrum Asia","headline":"Zydus and Synthon to commercialise novel 505(B)(2) oncology product in US market","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-02-12","type":"deal","source":"ET Pharma","summary":"Zydus acquires Synthon BV novel cancer drug marketing rights in US - ET Pharma","headline":"Zydus acquires Synthon BV novel cancer drug marketing rights in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPbkxFMmVRenJtaG5DcURpckNJbU1qaE4tSFQxX0tpbDMyNXNkckJuTEFtNVFlRG0zQXNpd09UTnJmMWFiU2Z3YXZkNUZiSlUyTUZ6VUpWNDJobGttUHNpY2ZUUVRMNXV5WlhjWXdNXzJRM28xc1Q3Rl9objluMHVnSkxwbVV3emJzQ1gxcjA4UkRPQVlud1ZLcXdzOUx2VFEzZ1JYNk16MkZuQlNwMjVValRRcnByN1dmNzk5S2JpWERQV0NHNTFzbXJ2WXRRWDZFQUhGWXpZOGZ2aXZkdlJYVnotNFNodw?oc=5","date":"2022-01-20","type":"patent","source":"IPWatchdog.com","summary":"Patent Filings Round-up: Claims from $25 Million Verdict Held Unpatentable After Stay Denied; Panel Denies IPR Over Lengthy Reexam History - IPWatchdog.com","headline":"Patent Filings Round-up: Claims from $25 Million Verdict Held Unpatentable After Stay Denied; Panel Denies IPR Over Leng","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOOFVZaWk2UUFwVjM0bjg5NE9jVWZJSEtRa2pCZkx4alFxLWIyNVZIcVVCWDE2WEtPRWd6SDVGUmo0bUhoQ3haeXlfaWRqbEFYQXBqemt6UDNqX2JuYzFWdjRmM05pTmFzMHJJRC03UmVaTVc3RVNvSXJHWlpXUGwxZ3lBbXFkUUpYUExjdw?oc=5","date":"2021-07-16","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Synthon prevails over Copaxone patent dispute - Generics and Biosimilars Initiative","headline":"Synthon prevails over Copaxone patent dispute","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}